Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 13

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q92995

UPID:

UBP13_HUMAN

Alternative names:

Deubiquitinating enzyme 13; Isopeptidase T-3; Ubiquitin thioesterase 13; Ubiquitin-specific-processing protease 13

Alternative UPACC:

Q92995; A8K2S3; B4DYF3; D3DNS2; Q96B25

Background:

Ubiquitin carboxyl-terminal hydrolase 13, also known as Deubiquitinating enzyme 13, plays a pivotal role in various cellular processes including autophagy, cell cycle progression, and DNA damage response. It achieves this by mediating the deubiquitination of several key proteins such as BECN1, MITF, and SKP2. This enzyme is a crucial component of the regulatory loop controlling autophagy and p53/TP53 levels, stabilizing PIK3C3/VPS34-containing complexes and thus promoting autophagy.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase 13 could open doors to potential therapeutic strategies.